Adèle de Masson

Cancer treatment and survivorship statistics, 2022

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

B cell regulation of the anti-tumor response and role in carcinogenesis

Regulatory B cells in inflammatory diseases and tumor

Inflammation and tumor progression: signaling pathways and targeted intervention

Temsirolimus in the treatment of mantle cell lymphoma

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017

The nonsystemic vasculitic neuropathies

Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors

Neuropathic Pain: From Mechanisms to Treatment

Current issues in chronic graft-versus-host disease

CCR4 as a Therapeutic Target for Cancer Immunotherapy

Cancer treatment and survivorship statistics, 2019

T‐cell exhaustion in HIV infection

How I treat mycosis fungoides and Sézary syndrome

Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?

Classification systems for chronic graft-versus-host disease

Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): Blinded histologic assessment of 35 cPAN cases

Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases

Blimp-1 overexpression is associated with low HIV-1 reservoir and transcription levels in central memory CD4+ T cells from elite controllers

Cutaneous and Mucosal Aphthosis during Temsirolimus Therapy for Advanced Renal Cell Carcinoma: Review of Cutaneous and Mucosal Side Effects of mTOR Inhibitors

Deficient regulatory B cells in human chronic graft-versus-host disease

Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD